Entities

Ancilia Biosciences uses CRISPR-based protection against bacteriophages to develop more durable live bacterial therapeutics and microbial products.

Bexson Biomedical develops subcutaneous drug formulations and delivery systems, including ketamine-based treatments for pain and mental health conditions.

Bloom Science develops microbiome-derived therapeutics that target gut-brain pathways for neurological and metabolic diseases.

Bright Minds Biosciences develops selective serotonin receptor drugs for neurological and psychiatric disorders, including epilepsy and depression.

Delix Therapeutics is a clinical-stage neuroscience company developing non-hallucinogenic small-molecule medicines that promote neuroplasticity. Its Neuroplastogen platform discovers compounds intended to strengthen neural connections and address psychiatric and neurological disorders. Its lead candidate zalsupindole (DLX-001) is being developed for major depressive disorder.

Freedom Biosciences develops ketamine and psychedelic-based drug regimens for neuropsychiatric disorders, with a focus on improving durability and safety.

Humans Anonymous operates an anonymous audio community where users can discuss mental health challenges and receive peer support.

ImYoo develops a patient-centered immune discovery platform using blood samples and molecular profiling to study immune responses and disease.

Iris Medicine develops small-binding RNA medicines for neurodegenerative diseases.

Maya Health developed measurement and clinical workflow software for psychedelic-assisted therapy. It now operates as NAITUR, building AI automation systems for healthcare practices, including patient intake, scheduling and administrative workflows.

Oral Genome develops saliva-based tests and microbiome analysis that provide personalized oral health insights and help identify dental disease risks.

Remepy develops hybrid treatments that combine pharmaceuticals with digital therapeutics designed to influence biological pathways and improve treatment outcomes.

Sanmai develops transcranial focused ultrasound technology for treating mental health conditions.

Sculpta Bio develops programmable RNA splicing medicines for complex brain diseases.

Tactogen develops novel entactogenic medicines designed to retain therapeutic benefits associated with MDMA while improving safety and tolerability.

Terran Biosciences develops new medicines and drug formulations for neurological and psychiatric disorders.

VisualizeMe develops smartphone-based body composition measurement using computer vision to estimate and track physical health metrics.

Xspan develops an AI platform for preventive health that combines personalized insights and agentic workflows to support long-term wellbeing.

Apollo Health Ventures current own career biography: Alexandra has dedicated her life to the improvement of health and medicine and co-founded Apollo with Nils and Ole in 2017. She is a Venture Partner at Apollo. She is deeply involved in Apollo’s Venture Lab where she focused on identifying company building opportunities through her close ties with global leading research institutes and researchers in the aging sector Alexandra worked in BCG’s healthcare practice specializing in biopharma strategy, market assessment and asset diligence She did her PhD studies at Harvard Medical School focusing on molecular mechanisms that contribute to cellular aging and is a trained pharmacist Outside appointments are source-published career context; a manager/issuer board role is not a personal financing check.

Physician-scientist and life sciences investor with a background in neurology and Alzheimer’s biomarkers; co-founder of EQT Life Sciences’ Dementia Fund.

Novoron Bioscience executive chairman and director, and Bright Minds Biosciences non-executive director; physician with neurological drug development experience at ACADIA, Proteostasis and Lumos.

Senior R&D adviser at Ovid Therapeutics, also described as executive R&D adviser in its biography and July 2026 announcement. A physician with pharmaceutical development experience across neurology and psychiatry; prior leadership includes Passage Bio, Acadia, Shire, Elan and Wyeth. Ovid’s biography confirms continued executive work at Delix Therapeutics.

Felix von Coerper is a managing partner and founder of ALS Investment Fund. The December 2025 announcement describes more than 25 years as an entrepreneur and life-sciences investor and identifies his Amylyx board appointment as former. His work concerns financing therapies for ALS and related neurodegenerative diseases.

Scientific and clinical adviser to Ovid Therapeutics. An NYU neurologist and epilepsy clinical trial researcher who also serves as chief scientific officer of the Epilepsy Foundation. Her existing advisory roles at Bloom Science, Neumirna, Axonis and Montara are preserved.

Co-founder and chief scientific officer of Bexson Biomedical; psychiatrist working in ketamine-assisted psychotherapy, applied genetics and functional nutrient science.

Mark Jacobstein serves Luminopia as Board Member. The company also identifies him as an executive business advisor at Immunai and formerly CUEO at Guardant Health.

Scientist and investor who co-founded Iris Medicine and Kelonia Therapeutics; previously worked at Venrock.

Melanie Leitner is chief scientific officer and a partner of ALS Investment Fund. The fund’s December 2025 announcement describes her as a neuroscientist with more than 25 years of translational research and development experience, including Biogen and Prize4Life. Her work concerns cross-sector ALS research and development.

Healthcare venture investor and venture partner at Think.Health, also listed by Angelini Ventures as a principal focused on digital health.

Jefferson Life Sciences strategic adviser and biotechnology partnerships executive. Previously led external innovation at Novo Nordisk; also serves on Aerska's board.

Allia Health develops an electronic health record and AI-supported practice platform for behavioral health clinicians, integrating intake, scheduling, documentation, billing and patient insights.

Awear develops a wearable EEG device and companion software for monitoring brain activity and helping users understand and regulate stress and emotions.

Breathwrk provides guided breathing exercises and programs through a mobile app to help users manage stress, improve sleep and train their breathing.

DeepWell DTx develops digital therapeutics and biofeedback technology that can be embedded in video games and media to support mental health.

Enara Health operates a technology-enabled weight management program combining personalized medical care, nutrition support and behavioral coaching.

Galen AI developed a personal AI health assistant that combined medical records and wearable data to provide personalized health insights. Oura acquired its technology and welcomed the team in April 2026.

GritWell operated a functional medicine clinic combining testing, clinician guidance and health coaching for chronic conditions. Its website now states that it has closed its doors to new patients.

HelloBiome develops microbiome sequencing, clinical research and AI analysis tools that help health and beauty companies design products, validate claims and interpret microbial data.

Instill builds organizational culture analytics tools that help employers measure team behavior and improve workplace culture and performance.

Jona combines at-home microbiome testing with AI analysis to explain gut health and generate personalized insights about food, supplements and lifestyle.

Medmain develops digital pathology software and AI tools for managing, analyzing and sharing pathological images used in medical diagnosis.

Metabolic Psychiatry Labs develops personalized mental health care based on metabolic assessment and targeted metabolic interventions.

Ozlo Sleep makes sleep-focused wireless earbuds and audio technology designed to mask disruptive sounds and help people fall and stay asleep.

Pangeam builds workplace intelligence software that uses spatial and behavioral data to help organizations understand and improve how people use their offices.

Skillprint uses gameplay data and AI to understand cognitive skills and personality, providing personalized games and assessments for wellbeing and performance.

WellSet provides employers and individuals with digital holistic wellness classes and programs covering mental, emotional and physical wellbeing.

George Church is Harvard’s Robert Winthrop Professor of Genetics and a researcher in genomic reading, writing and synthetic biology. Lila named him chief scientist in its 2025 launch-era statement. He is absent from Lila’s current published leadership roster, so continued company employment is unverified. Existing scientific advisory affiliations are preserved; a company role does not establish a personal investment.

Italian medical-device company developing soft, stretchable implantable electrodes for neuromonitoring, neuromodulation and brain-computer interfaces. Its Supersonic technology embeds electronic circuits in thin elastomeric films. Products include the WISE Cortical Strip for intraoperative brain monitoring and the Heron spinal-cord-stimulation lead under clinical development.

Medical executive and biotech entrepreneur who founded Gentium and has held multiple life-sciences board roles. IAG publishes Laura Iris Ferro as an external angel-network member. The member profile describes the following career and investing background, whose corporate positions are not independently asserted current: Presidente in Bio4Dreams. Life Science Manager e imprenditore nel settore Farmaceutico e biotech con esperienze internazionali. Laura è Specializzata nel settore Psichiatrico e clinico farmacologico. Attualmente Laura è Presidente di Bio4Dreams. Inoltre Laura è anche advisor per Panakes Partners, fondo di venture capital nel settore LifeScience. Champion:

Investment Analyst at Indaco, following an internship beginningMarch2025 and a permanent analyst appointment inSeptember2025. Holds a Milano-Bicocca economics degree and LIUC private-equity/finance training; own biography lists further postgraduate studies expected to finishOctober2026.

Senior Investment Manager at Indaco. Previously worked at Microsoft supporting financial-services digital transformation, advised the Italian Institute of Technology and founded We Start Italy after consulting at Accenture. Holds telecommunications-engineering degrees and a Bocconi MBA.

Venture Partner at Indaco with industrial-engineering and management training from Politecnico diMilano and Bocconi. Career includes enterprise telecommunications, Vodafone, DeutscheBank, RAI, Qualcomm and payments. Own biography describes seed-stage angel investing and corporate-innovation advisory work; no personal cash investments are inferred.

Elisa Beltrami is listed as Senior Investment Manager in an undated cached Indaco manager roster. Newer indexed team versions omit this name, so current employment is unconfirmed. Elisa is not assumed to be Elena Beltrami, a differently named BIO adviser listed elsewhere.

Head of Legal and HR at Indaco, responsible for corporate-secretarial, legal, organisational and personnel work. Previously led legal/compliance work atPensPlan InvestSGR and has lectured on financial regulation. Holds a law degree fromGenoa.

Francesco Zelano is listed as Senior Investment Manager in an undated cached Indaco manager roster. Newer indexed versions omit this name, so current affiliation is unconfirmed; original role and identity are preserved.

Partner and investment-committee member of Indaco BIO. Has biology, oncology, microbiology and business training, with a drug-development career including Intercept Pharmaceuticals, iDNA, Yaqrit and Zcube. Own biography also reports academic affiliations at UCL and Milano Bicocca.

Partner and investment-committee member of Indaco BIO sinceSeptember2022. Previously worked in drug discovery at Elan and Bioalvo, established and managed Hovione Capital and led business operations at Nanoform. Trained in microbiology/genetics inLisbon, biochemistry/pharmacy inMunich and business administration. Own profile heading misspells Gonzalo while biography and roster consistently use Goncalo.

Ilaria Ceccovecchi is identified in the manager-published team roster as Team Assistant. Additional career history is not verified from available primary sources.

Finance and Administration Assistant at Indaco. Previously worked in financial-services consulting atDeloitte/EY Luxembourg, fund administration atMC Square and corporate finance atFinsa. Holds LUISS management/corporate-finance and Bocconi strategy/entrepreneurship qualifications.

Raffaella Basile is identified in the manager-published team roster as Team Assistant. Additional career history is not verified from available primary sources.

Chief Financial Officer at Indaco. Previously CFO at Azimut LiberaImpresa and worked in administration and finance atOpera and CapeNatixis after financial-services auditing atDeloitte. Holds a Bocconi financial-markets degree and experience overseeing manager/fund accounts and regulatory relationships.

Venture Partner at Indaco. Previously led healthcare seed funds Eporgen Venture and Filarete Investimenti, worked in technology strategy consulting and helped build WishDays as COO before its2016 sale. Trained in economics and business atTorino and ESCP-EAP.

Indaco Venture Partners SGR S.p.A. is an Italian venture-capital asset manager based in Milan. Its own privacy notice establishes the exact legal company and address. Founded in2016 according to current company and founder biographies, it publicly launched the Indaco VenturesI fund inApril2018; these are different milestones. Its digital/deep-tech and medical-technology investing includes electronics, robotics, materials and neurovascular/brain-device companies. Its BIO strategy supports preclinical and clinical therapeutic development, including CNS indications. The manager is majority owned by management(51%), with IntesaSanpaolo and FuturaInvest minorities(24.5% each), as published in its governance directory. Managed funds are distinct from those shareholders and portfolio-company buyers. Historical Atlante and TT Venture vehicles remain individually identified. Current fund pages report AUM, not necessarily subscribed corpus or a final closing: overEUR363M aggregate is not recorded as a financing round. Original2018 launch disclosed EUR130M subscribed toIndacoVenturesI versus a target exceedingEUR200M; BIO announced an actual EUR95M first closing inMay2022 versus later EUR97M reportedAUM. Public team versions differ and inherited ElisaBeltrami/FrancescoZelano roles are preserved with undated/current-status qualification. ElenaBeltrami on the BIO adviser page is not automatically merged with Elisa. Public governance includes directors and statutory auditors. Genuine existing logo and ElizabethRobinson portrait are retained; publisher CAPTCHA blocks other original-photo retrieval, leaving explicit genuine-image gaps.

Indaco co-founder and Investment Director with an engineering and venture-investment background. Previously researched embedded and wireless systems at Berkeley, worked at McKinsey and joined IMI Fondi Chiusi in2009. Holds engineering degrees from Padua and Berkeley, including a PhD.

Indaco co-founder, board member and Investment Director. Serves investment committees for Indaco VenturesI and the Atlante funds, following more than twenty years in venture capital and private equity. Holds a Bocconi business degree and is a chartered accountant.

Co-founded Indaco in2016 and has led it as Managing Director. Previously led venture-capital activity at Intesa Sanpaolo, helping launch the Atlante funds after earlier private-equity work. Holds a Bocconi business degree and qualified as a chartered accountant in1995.

IAG publishes Elizabeth Robinson as an external angel-network member. The member profile describes the following career and investing background, whose corporate positions are not independently asserted current: Imprenditrice e venture capitalist settore BioTech. Life Science Laureata negli USA ma residente in Italia da piu di 30 anni, Elizabeth è una venture capital con diversi anni di esperienza nel settore life science. Elizabeth ama andare in bicicletta e il trekking. Champion: Elizabeth Robinson is identified in the manager-published team roster as Co-founder and Vice Chairman. Additional career history is not verified from available primary sources.

Investment Analyst at Indaco with earlier experience in fundraising and financial control at a space-technology startup and at PwC. Holds business-administration degrees from Luiss and Brescia, with study exchanges inChina and theNetherlands.

Sagard is a global alternative investment manager providing venture capital, private equity, private credit and real estate financing. Its venture businesses include Portage and Diagram; its Sagard AI Fund backs companies applying artificial intelligence across financial services and other industries.

BAG Ventures invests at pre-seed and seed in enterprise AI infrastructure, cybersecurity, edge computing and industry-specific software. Founded by former Google and CapitalG operators Bonita Stewart and Jackson Georges Jr., it supports startups with technical diligence, customer introductions and the affiliated BAG Collective operator community.

BizTrip builds an AI travel agent that lets employees book and manage complete business trips through natural-language requests.

Defendermate develops AI cybersecurity software for managing vulnerabilities and exposures, prioritizing exploitable threats and mapping attack paths.

Galvant develops AI data intelligence and workflow tools for manufacturers, connecting enterprise systems to improve back-office operations and reduce errors.

Kuddo develops an AI-supported clinical competency platform that helps behavioral health clinicians learn and apply evidence-based care.

Papr AI develops AI applications that automate sales and marketing workflows and connect go-to-market data and tools.

SXD develops AI design software that helps fashion and automotive manufacturers reduce material waste without changing their factory processes.

French medical-technology company operating as BCV Systems, developing actively steerable mechatronic guidewires for endovascular access and navigation. Shape-memory-alloy actuators and an electronically controlled handle adjust the guidewire tip for navigating complex blood vessels, including stroke-treatment procedures.

Medical-device company developing steerable microcatheters with three-dimensional control, torque transmission and an adjustable distal tip for endovascular interventions. Its applications include neuroradiology, interventional radiology and cardiology. Founded around Oz Cabiri’s catheter-development work in 2013.

Neurotechnology company developing EyeStat blink-reflex measurement devices and the i-blink mobile application. High-speed recordings and algorithms quantify eye responses to support neurological assessment, remote monitoring and research in traumatic brain injury and Parkinson’s disease. Previously known as Blinktbi.

Neurosurgical medical-device company developing the EVAC Endoport Vacuum Assisted Collection system for subdural hematoma drainage. The device uses a titanium construction and tapered lumen, designed to support minimally invasive drainage with compatibility for imaging workflows.

Neurovascular medical-device company developing venous stents for idiopathic intracranial hypertension and pulsatile tinnitus. Its River Stent system is designed for narrowed cerebral venous sinuses, with flexible construction and variable radial force. The company announced FDA Humanitarian Device Exemption approval for severe, refractory IIH in March 2026.

Adam Boehler is an investor and strategic adviser to Cortica. The company’s 2021 financing announcement identifies him as an individual participating investor, Rubicon Founders CEO, Landmark Health founder and former director of the Center for Medicare and Medicaid Innovation.

Benjamin Nathan leads technology and transformation at Cortica, including electronic records, software, analytics and information security. He previously led technology at UCLA’s medical school and served as deputy CIO at Weill Cornell. He holds a Columbia technology-management master’s degree.

Briana Elvaiah is Cortica’s CFO, overseeing finance, revenue-cycle management and human resources. She previously led finance at Correctional Medical Group Companies and Vericare, working in healthcare services and technology. She studied accounting at the University of San Diego.

Chris Hollander joined Cortica as chief marketing officer in 2025, leading marketing, partnerships, communications and enrollment. His earlier marketing leadership includes Amazon One Medical, Iora Health and Panera Bread. He also advises .406 Ventures and holds a Duke MBA.

Cindy Watson became Cortica’s COO in 2026, leading operations across the company. She previously served as Wellpath’s COO and has led healthcare organizations through several stages of growth. Her academic training is in communication disorders.

Elysa Marco co-directs the Cortica Innovation Network and practices pediatric cognitive and behavioral neurology. Her research addresses sensory processing, neurodevelopmental genetics, brain anatomy and treatment. She previously led sensory and autism programs at UCSF.

Kevin Shapiro co-directs the Cortica Innovation Network and leads research and therapeutic technologies. A pediatric neurologist and cognitive-neuroscience researcher, he studies brain development, speech, language and early brain injury. He earned medical and doctoral degrees at Harvard.

Kody Kinsley advises Cortica on strategy. He previously served as North Carolina’s health and human services secretary, working on Medicaid expansion, behavioral healthcare and medical debt. His current published biography also identifies advisory affiliations with Johns Hopkins and the Milken Institute.

Marc Spooner leads Cortica’s strategy, payer negotiations, analytics and value-based contracting. He previously served as COO of Point32Health and led commercial and government products at Tufts Health Plan. He studied at Harvard Business School and Duke.

Neil Hattangadi is Cortica’s co-founder and CEO. His background combines physician and scientific training with medical-device and biotechnology leadership, including Spirox and Volcano. He studied at Duke, Harvard Medical School and Oxford as a Rhodes Scholar.

Suzanne Goh co-founded Cortica and leads its medical practice. A pediatric behavioral neurologist, behavior analyst and neuroscience researcher, she developed the Cortica care model and has studied metabolic features, brain chemistry and neural circuitry in autism. She trained at Harvard, Oxford, UCSF and Columbia.

Medical-technology company developing a topical patch for vascular-access site preparation before needle insertion. The formulation combines local anesthetic delivery and vessel conditioning, with potential applications in neurovascular and cardiac catheterization. Its lead program remains in development toward an initial human pilot study.

Medical-device company developing endovascular access and delivery catheters for neurovascular procedures. Its ribbon-based catheter construction combines flexibility, pushability and stability for navigating complex blood-vessel anatomy. Co-founded by Martin Dieck and Brian Martin.

Medical-device company developing thrombectomy technology for neurovascular, peripheral and pulmonary applications. Its development portfolio includes ALGO, a smart aspiration system for clot removal. Led by co-founder and CEO Manning Hanser.

Digital-health company providing post-stroke virtual care through PRISM, combining remote monitoring technology with clinicians and care coordination. The program originated within Mount Sinai in 2019 and incorporated as a standalone company in 2022. Its company website describes AI-assisted monitoring for people recovering from stroke.